of CoronaVac a year, with a target completion date in September 2021. On 10 December, São Paulo Governor João Doria said that in the interim, prior to the local manufacture of CoronaVac, Instituto Butantan aimed to fill and finish 1 million doses of the vaccine per day. In April 2021, Sinovac said its third manufacturing plant for Coronavac was ready and had started manufacturing bulk vaccine ingredients, doubling its annual capacity to 2 billion doses. In April 2021, Bio Farma of Indonesia had filled and finished 35 million doses of CoronaVac, but was facing some production delays because of diminished supply of bulk delivered CoronaVac from China. In May 2021, Malaysian company Pharmaniaga obtained local approval for its fill and finish CoronaVac. In May 2021, Turkey was provided a license to produce CoronaVac. In May 2021, Hungary announced an agreement to fill and finish CoronaVac, with the goal to eventually manufacture it locally in a new plant in Debrecen. In June 2021, Egypt announced that it will produce about 40 million doses by the end of the year. Distribution of the locally produced vaccine will begin by August and it will be used locally and sent to other African nations. History Clinical trials Phase I–II In April 2020, CoronaVac began Phase I–II trials in China with 744 participants on adults over the age 18–59, and In May, CoronaVac began Phase I–II trials in China with 422 participants on elderly adults over the age 60 and above. Preliminary results indicate that neutralizing antibodies fell below the seropositive threshold 6 to 8 months after the first two doses, and that a third dose given 6 or more months after the second dose raised neutralizing antibody levels beyond that of an initial course consisting of 3 doses. In the Phase II trial completed in July 2020 published in The Lancet, CoronaVac showed seroconversion of neutralising antibodies for 109 (92%) of 118 participants in the 3 μg group, 117 (98%) of 119 in the 6 μg group, after the days 0 and 14 schedule; whereas at day 28 after the days 0 and 28 schedule, seroconversion was seen in 114 (97%) of 117 in the 3 μg group, 118 (100%) of 118 in the 6 μg group. Phase II results for older adults published in The Lancet showed CoronaVac was safe and well tolerated in older adults, with neutralising antibody induced by a 3